Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson's Disease With Cognitive Impairments”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 0 results

Early research (Phase 1)Looking for participantsNCT07216066
What this trial is testing

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

Who this might be right for
Parkinsons Disease
Regeneron Pharmaceuticals 46
Not applicableStudy completedNCT02048605
What this trial is testing

Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Patients With Parkinson's Disease

Who this might be right for
Parkinson's DiseaseMild Cognitive Impairment
University Hospital, Basel, Switzerland 30
Testing effectiveness (Phase 2)Study completedNCT05318937
What this trial is testing

Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Who this might be right for
Parkinson DiseaseCognitive Dysfunction
Supernus Pharmaceuticals, Inc. 86
Testing effectiveness (Phase 2)Looking for participantsNCT03836950
What this trial is testing

RTMS to Improve Cognition in Parkinson's

Who this might be right for
Parkinson's DiseaseMild Cognitive Impairment
VA Office of Research and Development 56
Testing effectiveness (Phase 2)WithdrawnNCT04810104
What this trial is testing

Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug

Who this might be right for
Parkinson DiseaseMild Cognitive Impairment
King's College London
Not applicableEnded earlyNCT02924194
What this trial is testing

Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease

Who this might be right for
Parkinson's DiseaseMild Cognitive Impairment
St. Joseph's Hospital and Medical Center, Phoenix 3
Testing effectiveness (Phase 2)Looking for participantsNCT07154511
What this trial is testing

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

Who this might be right for
Parkinson DiseaseParkinson Disease Dementia
Prabesh Kanel 45
Not applicableStudy completedNCT07262658
What this trial is testing

Cognitive Disparities in Parkinson's Disease

Who this might be right for
Parkinson Disease
Duke University 40
Testing effectiveness (Phase 2)Study completedNCT03774459
What this trial is testing

ANAVEX2-73 Study in Parkinson's Disease Dementia

Who this might be right for
Parkinsons Disease With Dementia
Anavex Life Sciences Corp. 132
Post-approval studies (Phase 4)UnknownNCT00696215
What this trial is testing

The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease

Who this might be right for
Parkinson's Disease
Istanbul University 40
Not applicableStudy completedNCT06920511
What this trial is testing

Cognitive Rehabilitation With Virtual Reality in Parkinson Disease

Who this might be right for
Parkinson DeseaseMild Cognitive Impairment (MCI)
Fondazione Don Carlo Gnocchi ETS 10
Not applicableStudy completedNCT03330470
What this trial is testing

Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease

Who this might be right for
Subjective Cognitive ImpairmentMild Cognitive ImpairmentParkinson Disease+1 more
Slovak Academy of Sciences 26
Not applicableStudy completedNCT07240272
What this trial is testing

TACS Modulates Speech and Cognitive Impairments in People With PD by Targeting the Medial Frontal Cortex

Who this might be right for
Parkinson Disease
Ke Dong, MD 28